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SUMMARY

Uropathogenic Escherichia coli (UPEC) cause urinary tract infections (UTIs) by invading urothelial cells. In
response, the host mounts an inflammatory response to expel bacteria. Here, we show that the NF-E2-related
factor 2 (NRF2) pathway is activated in response to UPEC-triggered reactive oxygen species (ROS) production. We demonstrate the molecular sequence of events wherein NRF2 activation in urothelial cells reduces
ROS production, inflammation, and cell death, promotes UPEC expulsion, and reduces the bacterial load. In
contrast, loss of NRF2 leads to increased ROS production, bacterial burden, and inflammation, both in vitro
and in vivo. NRF2 promotes UPEC expulsion by regulating transcription of the RAB-GTPase RAB27B. Finally,
dimethyl fumarate, a US Food and Administration-approved NRF2 inducer, reduces the inflammatory
response, increases RAB27B expression, and lowers bacterial burden in urothelial cells and in a mouse
UTI model. Our findings elucidate mechanisms underlying the host response to UPEC and provide a potential
strategy to combat UTIs.

INTRODUCTION
Urinary tract infections (UTIs) are the most common infections,
accounting for approximately eight million clinic and emergency
department visits per year in the United States (Dielubanza and
Schaeffer, 2011). Additionally, UTIs commonly recur and often
become antibiotic resistant. More than 85% of UTIs are caused
by uropathogenic Escherichia coli (UPEC) (Dielubanza and
Schaeffer, 2011) that are able to use type-1 fimbria to attach to
uroplakin proteins on the luminal surface of superficial cells of
the urothelium (Zhou et al., 2001). UPEC can then enter the urothelial cells via endocytosis of uroplakins (Khandelwal et al.,
2010) or via adaptors such as clathrin and AP-2 (Eto et al.,
2008). Most UPEC transiently colonize urothelial cells, but
some enter autophagosomes to form quiescent intracellular reservoirs (Wang et al., 2012a, 2012b, 2019) that can seed recurrent
infections (Martin-Sanchez et al., 2018; Mysorekar and Hultgren,
2006; Wang et al., 2012b).
The innate immune response generated by bladder epithelial cells limits both acute and persistent infections in several
ways. Initially, Toll-like receptor 4 (TLR4) on urothelial cells
recognizes UPEC and activates a signaling cascade, leading
to the secretion of pro-inflammatory cytokines such as interleukin (IL)-6 and IL-1b (Bishop et al., 2007; Schilling et al.,
2001). After they are invaded with bacteria, the urothelial cells
exocytose the bacteria in a process that relies on the Rab

GTPase RAB27B (Dhakal and Mulvey, 2009; Khandelwal
et al., 2009; Song et al., 2009). This expulsion may also involve
autophagy, as mice with reduced expression of the autophagy
gene Atg16L1 cleared bacteria from their bladders faster than
wild-type (WT) mice (Wang et al., 2012a). Furthermore, mice
expressing the human variant ATG16L1T300A had elevated expressions of RAB27B, RAB11A, and RAB33B and cleared
UPEC more efficiently than mice expressing WT ATG16L1
(Wang et al., 2019).
Another way the bladder can clear UPEC is by exfoliating the
superficial urothelial layer, thereby shedding bacteria into the
lumen. The shedding also helps recruit innate immune cells
including polymorphonuclear leukocytes, monocytes, and
macrophages that attack the bacteria (Stemler et al., 2013; Davis et al., 2005; Smith et al., 2008). Though effective means of
bacterial clearing, exfoliation and inflammation lead to extensive tissue damage that needs to be repaired to restore the
barrier function of the bladder (Liu et al., 2019; Mysorekar
et al., 2009). In many organs, tissue damage is associated
with an increased production of reactive oxygen species
(ROS) (Mittal et al., 2014). Elevated ROS may occur during
UTIs, as the urine of patients with acute UTI contained malondialdehyde, a byproduct of oxidative stress and marker of lipid
peroxidation (Kurutas et al., 2005). In addition, UPEC elaborate
a number of genes involved in oxidative stress response (Johnson et al., 2006; Hryckowian and Welch, 2013; Tree et al., 2008;
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Bessaiah et al., 2019; Himpsl et al., 2020; Ambite et al., 2021).
However, ROS has not been directly quantitated in UPEC-infected urothelial cells.
If urothelial cells do have increased ROS during UPEC infection, then the cells must have a mechanism to maintain redox homeostasis, as ROS build-up is detrimental for vesicle transport
(Ravi et al., 2016) and thus may impair UPEC expulsion. Here,
we asked whether the transcription factor NF-E2-related factor
2 (NRF2) (Tonelli et al., 2018) plays a role in managing ROS
and UPEC in bladder epithelial cells. We focus on NRF2 because
oxidative stress causes NRF2 to dissociate from its negative
regulator Kelch-like ECH associated protein 1 (KEAP1) in the
cytoplasm and translocate to the nucleus, where NRF2 binds
to antioxidant response elements (AREs) to promote transcription of antioxidant genes such as NAD(P)H quinone dehydrogenase 1 (NQO1), glutamate-cysteine ligase catalytic subunit
(GCLC), and heme oxygenase 1 (HMOX1) (Itoh et al., 1999).
Additionally, NRF2 plays a role in modulating cellular metabolism
in various infections (Nairz et al., 2013; Athale et al., 2012), and
high NRF2 activity decreases secretion of pro-inflammatory cytokines such as IL-6 and IL-1b (Kobayashi et al., 2016). We show
that UPEC infection triggers both ROS production and NRF2
pathway activation in urothelial cells, leading to the activation
of NRF2 targets involved in oxidative homeostasis. Moreover,
we show that NRF2 activation increases RAB27B expression.
Finally, we demonstrate that treatment with an NRF2 activator
can reduce UPEC burden in urothelial cells in vitro and in mouse
bladders in vivo.
RESULTS
UPEC infection triggers ROS production and activates
the NRF2 pathway in urothelial cells
To test the hypothesis that UPEC infection promotes the production of ROS in urothelial cells, we infected human 5,637
bladder carcinoma epithelial cells (henceforth referred to as urothelial cells) with UPEC (UTI89, a clinical isolate) (Hung et al.,
2009) for up to 8 h, washed them thoroughly, and stained them
with the ROS indicator dye 20 ,70 -dichlorodihydrofluorescein diacetate (H2DCF). ROS accumulation was evident in urothelial
cells as early as 1 h post-infection (hpi) (Figures 1A and 1B),
peaked at 3 hpi, and decreased to baseline by 8 hpi (Figure 1C).
Treatment with lipopolysaccharide (LPS), a component of
Gram-negative bacteria, also triggered ROS production as
early as 15 min post-treatment (Figure 1D). ROS induction
could be mitigated at 1 hpi by treating the cells with the ROS
scavenger N-acetyl-L-cysteine (NAC) (Zhang et al., 2011)
(Figure 1B).
The decline in ROS abundance at 6 and 8 hpi suggested that
an anti-redox response pathway was activated. To determine
whether NRF2 was activated in response to infection in urothelial
cells, we performed immunofluorescence staining. At 0 hpi,
NRF2 was predominantly cytoplasmic, but by 6 hpi, it was predominantly nuclear (Figures 1E, S1A, and S1B). Cell fractionation
experiments confirmed this finding (Figure S1C). Furthermore,
quantitative RT-PCR (qRT-PCR) showed that the NRF2 targets
GCLC and HMOX1 were upregulated at 6 and 8 hpi (Figure 1F)
as compared to uninfected cells. Together, our observations
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suggest that UPEC infection triggers ROS production and activates NRF2 in urothelial cells.
UPEC infection triggers p62-dependent NRF2 activation
via release from KEAP1
We next wanted to determine the mechanism by which NRF2
translocates to the nucleus. NRF2 is sequestered by KEAP1,
which normally interacts with p62, a protein that tags organelles
for autophagic engulfment. When autophagy is activated, both
p62 and KEAP1 are degraded via lysosomes and autolysosomes
(Katsuragi et al., 2015; Lau et al., 2010). To determine whether
NRF2 was enacting this cellular program, we followed KEAP1
and p62 expression in cells during the time course of infection.
Thus, we measured p62 and KEAP1 abundance in infected cells
by western blot and found that both proteins were significantly
lower at 6 and 8 hpi than at 0, 1, and 3 hpi (Figures 2A and B).
We verified the effect on NRF2-KEAP1 interaction by co-immunoprecipitation, which was carried out using an anti-NRF2 antibody and the levels of its binding partner KEAP1 measured during the infection. Co-immunoprecipitation data show significant
dissociation of NRF2-KEAP1 complex post-infection (Figure 2C),
verifying the release of NRF2 and its migration to the nucleus
(Figures S1A–S1C). Consistent with these findings, the interaction between p62 and KEAP1 is maintained over the early
hours of infection, but the interaction and abundance of each
protein are decreased by 6 and 8 hpi. (Figures 2A, 2B, and S2).
Immunofluorescence analysis revealed that p62 and KEAP1
co-localized with the acidic compartment marked by LysoTracker significantly more at 6 hpi than at 0 hpi (Figures 2D–2F
and S3C–S3E). Further, KEAP1 and p62 were found to colocalize with lysosome marker LAMP1 (Figures S3A and S3B).
We conclude that, upon infection, KEAP1 dissociates from
NRF2 and continues to associate with p62 and then possibly is
degraded in the lysosome, thereby releasing and allowing
NRF2 to translocate to the nucleus in urothelial cells (Figure 2G).
Next, we sought to confirm whether p62 accumulation was
key for NRF2 pathway activation. We took a pharmacological
approach to modulate autophagy and thereby p62 levels by
treating urothelial cells with two drugs with opposing actions
on autophagic activity. First, we treated cells with the lysosome
blocker and autophagy inhibitor DCAP (2-((3-(3, 6-dichloro-9Hcarbazol-9-yl)-2-hydroxypropyl) amino)-2-(hydroxymethyl) propane-1, 3-diol), which we previously showed leads to p62 accumulation in urothelial cells (Allavena et al., 2018). We anticipated
that accumulated p62 would bind KEAP1, which would release
NRF2. As expected, DCAP treatment induced NRF2 translocation to the nucleus (Figures 3A and S4) and activated the NRF2
pathway, as evidenced by increased expression of the NRF2 targets NQO1, GCLC, and HMOX1 (Figure 3B). Second, we treated
cells with rapamycin, which activates autophagy and leads to
p62 degradation. Consistent with the idea that decreased p62
abundance would allow KEAP1 to bind NRF2 and retain NRF2
in the cytoplasm (Figures 3A and S4), we found that expression
of the NRF2 target genes NQO1 and GCLC was decreased in rapamycin-treated urothelial cells (Figures 3C and S4). Together,
our findings revealed that UPEC infection leads to a transient increase in p62 levels, which then activates the NRF2 redox stress
response.
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Figure 1. UPEC infection triggers ROS response and NRF2 pathway activation in bladder epithelial cells
(A) H2DCF staining of ROS (green) in uninfected and UPEC infected bladder epithelial cells at indicated time points. Scale bar, 200 mm. The arrows show
representative cells displaying H2DCF staining for ROS.
(B) Quantitation of H2DCF in relative fluorescence units (RFUs) in cells treated as indicated. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01,
***p < 0.001 compared with 0 hpi by two-way ANOVA with Tukey’s multiple comparisons test.
(C) Quantitation of H2DCF in RFUs in cells at indicated hours of post-UPEC infection. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01 compare
with 0 hpi by two-way ANOVA with Tukey’s multiple comparisons test.
(D) Quantitation of H2DCF in RFUs in cells treated with the vehicle (PBS) or 0.5 mg LPS. Data are presented as mean ± SD (n = 3 experiments). ***p < 0.001
compare with the vehicle by an unpaired two-tailed Student’s t test.
(E) Immunostaining for NRF2 (green) in uninfected and UPEC-infected cells at the indicated time points. Scale bar, 20 mm. Nuclei are stained blue.
(F) qRT-PCR analysis of NRF2 targets NQO1, GCLC, and HMOX1 at indicated times post-infection.
Data are presented as mean ± SD (n = 3 experiments). ns, non-significant, *p < 0.05, ***p < 0.001 compared with 0 hpi by two-way ANOVA with Tukey’s multiple
comparisons test.

Constitutive activation of NRF2 reduces oxidative stress
and bacterial burden
We next took two complementary approaches to determine the
effects of NRF2 activity on UPEC infection in urothelial cells.
First, we sought to determine the effect of constitutive NRF2 acti-

vation. To do so, we used CRISPR-Cas9 to create urothelial cells
in which KEAP1 lacks the first two Kelch repeats (Itoh et al.,
1999) and thus should not bind NRF2, allowing NRF2 to accumulate and enter the nucleus constitutively (McMahon et al., 2003)
(Figure S5A). After confirming that Cas9 deleted the nucleotide
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Figure 2. p62 dependent KEAP1 sequestration post-infection leads to NRF2 activation
(A and B) Western blot and densitometric quantitation of p62 (A) and KEAP1 (B) in urothelial cell lysates at indicated time points after infection. GAPDH serves as a
loading control. Data are presented as mean ± SD (n = 3 experiments). ns, non-significant *p < 0.05, **p < 0.01 compared with 0 hpi by two-way ANOVA with
Tukey’s multiple comparisons test.
(C) Western blot and densitometric quantitation of anti-NRF2 immunoprecipitate (IP) with the anti-KEAP1 antibody at indicated time points post-infection. Data
are presented as mean ± SD (n = 3 experiments). ***p < 0.001, ****p < 0.0001 compared with 0 hpi by two-way ANOVA with Tukey’s multiple comparisons test.
(D and E) Immunostaining for p62 (green in D) and KEAP1 (green in E) with LysoTracker (red) at indicated time points. Arrows indicate lysosomal localization of
KEAP1 and p62. Nuclei are stained blue (DAPI). Scale bar, 20 mm.
(F) Immunostaining for p62 (green), KEAP1 (magenta), and lysosome (LysoTracker, red) at indicated time post-infection. Arrows indicate triple co-localization.
Yellow arrowheads mark UPEC. Nuclei are stained blue (DAPI). Scale bar, 20 mm.
(G) Schematic representation of p62-KEAP1-NRF2 interaction.
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Figure 3. Autophagy modulators regulate NRF2 localization and pathway activation
(A) Immunofluorescence localization of NRF2 (green) in bladder epithelial cells treated with indicated chemical modulators. Arrows indicate NRF2 expression.
Scale bar, 20 mm. DAPI stained nucleus (blue). Data are representative of 3 independent experiments.
(B and C) Quantitative PCR of the NRF2 targets in cells treated with (B) DCAP or (C) Rapamycin (Rap) overnight (18 h).
Data are presented as mean ± SD (n = 3 experiments). ns, non-significant, *p < 0.05, **p < 0.01 compared with vehicle control by two-tailed unpaired Student’s
t test.
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Figure 4. Constitutive activation of NRF2 reduces oxidative stress and bacterial burden
(A) Western blot and densitometric quantitation of NRF2 and GAPDH (loading control) in control and KEAP1/ cells. Data are presented as mean ± SD (n = 3
experiments). **p < 0.01 compared with control by unpaired two-tailed Student’s t test.
(B) qRT PCR analysis of NRF2 targets in KEAP1/ urothelial cells. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01, ***p < 0.001 compared with
control by two-tailed unpaired Student’s t test.
(C and D) Quantitation of H2DCF in RFUs in indicated uninfected cells (C) and infected cells (D) at the indicated time points. Data are presented as mean ± SD
(n = 3 experiments). **p < 0.01 compared with control uninfected cells in (C) by two-tailed unpaired Student’s t test. ns, non-significant, ***p < 0.001 compared
with control infected cells in (D) by two-way ANOVA Tukey’s multiple comparisons test.
(E–H) ELISA data indicating concentrations of (E) IL-6 and (F) IL-1b in uninfected cells and (G) IL-6 and (H) IL-1b in 6 hpi infected cells. Data are presented as mean
± SD (n = 3 experiments). *p < 0.05 compared with control or 0 hpi by two-tailed unpaired Student’s t test.
(I) UPEC expulsion assay in KEAP1/ and control cells at the indicated time points. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01 compared
with control using two-way ANOVA Tukey’s multiple comparisons test.
(J) UPEC intracellular bacterial count in control and KEAP1/ cells at 24 hpi. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01 compared with
control by two-tailed unpaired Student’s t test.
(K) Quantitation of intracellular bacteria in control and KEAP1 siRNA cells at 24 hpi. Data are presented as mean ± SD (n = 3 experiments). ***p < 0.001 compared
with control scrambled siRNA by two-tailed unpaired Student’s t test.

sequence corresponding to the Kelch repeats (Figure S5B), we
performed western blots of KEAP/ urothelial cells and found
that, as expected, they contained significantly higher levels of
NRF2 protein than WT cells (Figure 4A). We performed nuclear
fractionation in WT and KEAP1/ cells followed by immunoblotting for NRF2 and show that the NRF2 protein is in the nuclear
fraction of KEAP1/ cells (Figure S5D). Compared to WT cells,
KEAP1/ cells expressed more of the NRF2 targets NQO1,
GCLC, and HMOX1 (Figure 4B) and had less ROS both before
(Figure 4C) and during (Figure 4D) UPEC infection. In macrophages, NRF2 activation blocks the expression of inflammatory
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cytokines such as IL-6 and IL-1b (Kobayashi et al., 2016).
Accordingly, compared to WT cells, KEAP1/ urothelial cells
had significantly lower IL-6 (40-fold) and IL-1b (8-fold)
mRNA abundance (Figures S5E–S5H). In addition, we note
decreased secretion of IL-6 in both uninfected (Figure 4E) and infected (Figure 4G) cells. In contrast, while IL-1b levels are
decreased in the absence of KEAP1 (Figure 4F), levels are not
further affected upon infection (Figure 4H). Although at 1 hpi
KEAP1/ cells were similarly infected as control cells (Figures
S6A and S6B), by 24 hpi, they exhibited greater survival (Figure S6C), had a higher rate of UPEC expulsion (Figure 4I), and
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harbored fewer intracellular bacteria (Figure 4J) than WT cells.
Similar results were noted where KEAP1 was depleted with
siRNA (Figure 4K). These data indicate that depletion of constitutive KEAP1 leads to nuclear translocation of NRF2 and activation
of NRF2 pathway activity, which reduces oxidative stress and
promotes UPEC clearance in bladder epithelial cells.
NRF2 is necessary to alleviate oxidative stress and limit
bladder inflammation
As a second approach to determine the effects of NRF2 activity
on UPEC infection in urothelial cells, we used small interfering
RNA (siRNA)to knock down NRF2 expression in urothelial cells.
Compared to cells that received control siRNA, cells that
received NRF2 siRNA had more ROS (Figure 5A) and less
UPEC expulsion (Figure 5B) at both 3 and 6 hpi. The reduction
in expulsion was not due to decreased or impaired infectivity,
as cells treated with NRF2 siRNA were equally infected at 1 hpi
(Figure S6D). To explore the connection between increased
ROS and decreased UPEC expulsion, we treated WT cells with
the ROS inducer tert-Butyl hydroperoxide (tBHP). This treatment
significantly inhibited UPEC expulsion. Treatment with NAC and
tBHP caused an intermediate level of expulsion, but NAC treatment alone did not significantly affect expulsion (Figure 5C), indicating that ROS scavenging alone is not sufficient to clear UPEC
but also needs NRF2 activation in bladder epithelial cells. Taken
together, our findings indicate that NRF2 activation reduces
oxidative stress and promotes UPEC clearance.
To confirm our in vitro results, we obtained Nrf2 knockout
(Nrf2/) mice. As expected, bladders from Nrf2/ mice expressed less Nrf2 and less of the NRF2 targets Nqo1, Gclc,
and Hmox1 than WT mice (Figure S7). We transurethrally administered UPEC and followed the time course of UTI response.
Whereas WT mice showed evidence of exfoliated urothelial cells
in their urine only upon infection (Figures 5D and 5E), urine from
Nrf2/ mice showed profound exfoliation of urothelial cells both
before (Figures 5F and 5H) and during (Figure 5G) infection.
These exfoliated cells contained abundant ROS, as indicated
by H2DCF staining (Figure 5L). Additionally, urine from infected
Nrf2/ mice continued to show a relatively higher inflammation
index by 72 hpi compared with WT mice (Figure 5I). Moreover,
serum IL-6 and IL-1b responses were higher in infected
Nrf2/ mice than in WT mice, indicating an overall elevated inflammatory response due to loss of NRF2 activity (Figures 5J
and 5K). Nrf2/ mice were equally as infected as WT controls
(Figure S6E), similar to NRF2 siRNA-treated cells (Figure S6D).
However, Nrf2/ mice exhibited significantly reduced levels of
bacteriuria at this time point (Figure 5M). These findings could
suggest that the Nrf2/ bladders are deficient in expelling bacteria because of increased ROS levels, increased superficial
epithelial cell exfoliation, or possibly increased infection of underlying cells, which are exposed because of superficial cell
exfoliation (Mysorekar and Hultgren, 2006). Thus, the in vivo
data corroborate the in vitro data, indicating that NRF2 plays
an important role in the host response to UTIs.
NRF2 promotes UPEC expulsion via RAB27B
Our results thus far establish the correlation between the NRF2
activation and UPEC expulsion. Therefore, we sought to deter-
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mine the mechanism by which NRF2 promotes UPEC expulsion.
Earlier work has shown that the small Rab GTPases RAB27B,
RAB33B, and RAB11A are implicated in UPEC expulsion (Miao
et al., 2017; Wang et al., 2019). To determine whether NRF2,
which regulates its target genes by binding AREs in the promoter
regions, directly activated the Rabs involved in UPEC expulsion,
we used a promoter alignment analysis tool for the identification
of putative transcription factor binding sites in a given genomic
region surrounding coding or non-coding genes (ConTra v3)
(Kreft et al., 2017). We identified one such consensus sequence
at 345 bp upstream of the RAB27B transcription start site (TSS)
and found that this sequence was evolutionarily conserved (Figure 6A). AREs were not noted in the RAB11A or RAB33B
genomic regions. To confirm that NRF2 binds this ARE, we performed chromatin immunoprecipitation (ChIP) with an NRF2specific antibody in urothelial cells. This analysis revealed that
NRF2 binds to ARE in the RAB27B promoter, though it did not
bind the TSS or untranslated region of the chromosome (Figure 6B). Consistent with NRF2 binding to RAB27B promoter,
we also observed RAB27B expression was activated at the
6 hpi concomitant with activation of NRF2 (Figures 6C and S1).
Interestingly, RAB27B appears to move from a predominantly
perinuclear localization to a cellular periphery between 1 and
6 hpi before returning to perinuclear space (Figure S8).
In line with our findings, KEAP1/ cells (which have constitutively active NRF2) expressed significantly more RAB27B protein
and transcript than did WT cells (Figures 6D and 6E). However,
KEAP1/ and WT cells expressed similar amounts of RAB11A
and RAB33B proteins (Figure 6D). Conversely, cells in which
NRF2 was knocked down with siRNA expressed significantly
less RAB27B protein and transcript than control cells (Figures
6F and 6G). Likewise, bladders from Nrf2/ mice expressed
significantly less Rab27b transcript than did bladders from WT
mice (Figure 6H). Finally, DCAP treatment, which induces
NRF2, also increased RAB27B expression in urothelial cells (Figure 6I). Together, these experiments confirm that NRF2 transcriptionally regulates RAB27B expression in urothelial cells
and thus may contribute to UPEC expulsion.
Dimethyl fumarate treatment activates NRF2 and
reduces bacterial burden
Given our data suggesting that NRF2 activation contributes to
UPEC clearance in urothelial cells, we examined the effects of
the NRF2 pathway activator dimethyl fumarate (DMF) (Satoh
and Lipton, 2017), a US Food and Drug Administration-approved
drug for treating relapsing multiple sclerosis (Satoh and Lipton,
2017). DMF treatment of urothelial cells induced the NRF2
pathway as shown by NRF2 nuclear translocation (Figures 7A
and S4) and concomitant increase in expression of NQO1,
GCLC, and HMOX1 (Figure 7B). Furthermore, DMF-treated cells
had a lower intracellular bacterial burden at 24 hpi than vehicletreated cells when treated with the drug at the same time as
UPEC infection (Figure 7C). Given a report that high concentrations of DMF (200 ppm) could possibly directly kill bacteria
(Wang et al., 2001), we pretreated cells with a significantly lower
concentration of 50 mM DMF (7.2 ppm) and washed the cells to
remove residual DMF prior to infecting them. This treatment
also reduced the bacterial burden (Figure 7C). DMF treatment
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Figure 5. NRF2 is necessary to alleviate oxidative stress and limit bladder inflammation
(A) Quantitation of H2DCF in UPEC-infected urothelial cells treated with control siRNA or NRF2 siRNA. Data are presented as mean ± SD (n = 3 experiments).
*p < 0.05 compared with control siRNA using two-way ANOVA Tukey’s multiple comparisons test.
(B) Quantitation of UPEC expulsion in UPEC-infected urothelial cells treated with control siRNA or NRF2 siRNA. Data are presented as mean ± SD (n = 3
experiments). **p < 0.01, ***p < 0.001 compared with control siRNA using two-way ANOVA Tukey’s multiple comparisons test.
(C) Quantitation of UPEC expulsion in UPEC-infected urothelial cells treated as indicated. Data are presented as mean ± SD (n = 3 experiments). ns, non-significant, *p < 0.05, **p < 0.01, ***p < 0.001 compared with vehicle treatment using two-way ANOVA Tukey’s multiple comparisons test.
(D–G) Representative urine cytology images of (D) uninfected WT mice, (E) WT mice, 24 hpi, (F) uninfected Nrf2/ mice, and (G)Nrf2/ mice, 24 hpi. Arrows
indicate exfoliated urothelial cells; arrowheads indicate infiltrated immune cells.
(H) Quantitation of exfoliated cells in uninfected mice of the indicated genotypes. Data are presented as mean ± SD (n = 14 mice of each genotype). *p < 0.05
compared with WT by two-tailed unpaired Student’s t test.
(I) Graph of inflammation score of urines obtained from mice of the indicated genotypes at the indicated time points post-infection. Data are presented as
mean ± SD (n = 10 animals in each group). ns, non-significant, *p < 0.05 compared with respective hpi in WT by two-tailed unpaired Student’s t test.
(J and K) ELISA data showing concentrations of (J) IL-6 in indicated mice and (K) IL-1b in indicated mice. Data are presented as mean ± SD (n = 10 animals in each

group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared respective condition (as indicated) by one-way ANOVA Sı́dák’s
multiple comparisons test.
(L) H2DCF staining of exfoliated cells obtained from uninfected mice of the indicated genotypes. DAPI stains nuclei. Scale bar, 100 mm (WT) and 200 mm (Nrf2/).
(M) Urinary bacterial load in WT and Nrf2/ mice at 6 hpi. Data are presented as mean ± SD (n = 14 animals of each genotype). **p < 0.01 compared with WT by
two-tailed unpaired Student’s t test.
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Figure 6. NRF2 promotes UPEC expulsion via RAB27B
(A) ConTra v3 analysis showing consensus sequence of AREs in RAB27B promoter (red box); sequence logo representing the position weight matrix for the
detected binding site.
(B) Schematic depiction of RAB27B promoter region showing TSSs, AREs (red) 345 bp upstream of TSSs, and the position of each primer set. The respective gels
show amplified products from input, NRF2 pull down, IgG pull down, and No Template Control (NTC). The right gel shows results of PCR with primers that amplify
an untranscribed region. 100 bp MW ladder was used.
(C) Western blot and densitometric quantitation of RAB27B and GAPDH (loading control) in uninfected and infected urothelial cells. Data are presented as mean ±
SD (n = 3 experiments). *p < 0.05, **p < 0.01 compared with 0 hpi by two-way ANOVA with Tukey’s multiple comparisons test.
(D) Western blot and densitometric quantitation of RAB27B, RAB11A, and RAB33B proteins in indicated cells. GAPDH, loading control. Data are presented as
mean ± SD (n = 3 experiments). ns, non-significant, ***p < 0.001 compared with control by two-tailed unpaired Student’s t test.
(E) qRT PCR analysis of RAB27B gene expression in indicated cells. Data are presented as mean ± SD (n = 3 experiments). ***p < 0.001 compared with control by
two-tailed unpaired Student’s t test.

(legend continued on next page)
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increased the rate of UPEC expulsion (Figure 7D), increased
RAB27B expression (Figure 7E), and decreased expression of
IL-6 and IL-1b (Figures 7F and 7G). These data suggested that
DMF could be used to protect urothelial cells from UPEC
infection.
To further test the utility of DMF, we induced a UTI in mice pretreated with DMF or vehicle. DMF pretreatment did not inhibit the
establishment of infection (Figure S6F). Both vehicle- and DMFtreated mice exhibited high urine inflammation scores at 24 hpi
(Figure 7J). However, at 48 hpi, DMF-treated mice had a lower
urinary bacterial load (Figure 7H), fewer exfoliated urothelial cells
in urine (Figure 7I), and lower immune cell infiltration in urine than
vehicle-treated mice (Figure 7J). Furthermore, DMF-treated
mice continued to show lower bacterial load in the urine (Figure 7H) and in bladder tissue (Figure 7K). DMF-treated mice
also exhibited reduced inflammatory cytokines, IL-6 and IL-1b
secretion at both 24 and 72 hpi (Figures 7L–7O) Together, our
in vitro and in vivo data suggest that pharmacological activation
of NRF2 reduces inflammation and promotes bacterial expulsion, thereby reducing bacterial load and cell damage during a
UTI.
DISCUSSION
Together, our work demonstrates that NRF2 promotes urothelial response to UPEC infection in several ways. First, in
response to increased ROS, NRF2 is activated and enters the
nucleus to mediate the transcription of antioxidant response
genes. Second, NRF2 activation leads to reduced ROS, inflammation, bacterial load, and cell death in infected urothelial cells.
Third, in vivo, loss of NRF2 leads to increased inflammation and
bladder exfoliation. Fourth, whereas NRF2 activation promotes
UPEC expulsion, loss of NRF2 reduces UPEC expulsion in vitro.
This may be explained by the fact that NRF2 regulates transcription of RAB27B, which promotes UPEC expulsion. Finally,
treatment with the NRF2 activator DMF leads to increased
expression of antioxidant response genes, decreased expression of inflammatory cytokines IL-6 and IL-1b and reduced
immune cell influx to the mucosa, indicative of reduced overall
inflammatory response along with decreased bacterial burden
in urine and tissue.
Our data are consistent with previous models (Katsuragi et al.,
2015) regarding the mechanism by which p62 modulates NRF2
activation. We show that p62 concentration in cells increases
by 1 hpi then decreases by 6 hpi. At 6 hpi, KEAP1 concentration
also decreases, and both proteins co-localize with lysosomes.
Thus, our data suggest that UPEC infection causes a transient increase in p62 as reported previously (Miao et al., 2015) and
which we now show binds KEAP1 and targets itself and
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KEAP1 for destruction. Interestingly, although KEAP1 dissociates from NRF2 early in infection, it continues to associate with
p62 as it is targeted to the lysosome for degradation. On the
other hand, NRF2 is released and allowed to enter the nucleus
to activate the transcription of antioxidant response genes as
well as RAB27B. It is also possible that KEAP1 is directly
oxidized by ROS, causing it to be degraded and allowing NRF2
activation. However, our observation that blocking autophagy
with DCAP (Allavena et al., 2018) led to NRF2 activation supports
the idea that p62 accumulation promotes KEAP1 release of
NRF2. We further found that DCAP treatment activates not
only the NRF2 pathway but also activates RAB27B expression
to reduce the bacterial load in bladder epithelial cells. Therefore,
our data establish a link between antioxidant response and
expulsion of UPEC via transcriptional regulation of RAB27B
expression.
An important outcome of NRF2 activation is decreased
inflammation and oxidative stress, which we observed as
reduced ROS and IL-6 and IL-1b mRNA levels in uninfected
KEAP1/ cells. Conversely, the loss of Nrf2 in mice led to
ROS and exfoliation in the bladder even in the absence of
infection. Our in vitro data are consistent with recent work (Kimura et al., 2018), demonstrating that elevated expression of
the NRF2 target NQO1 could inhibit the activation of inflammatory cytokines and suppress the IL-6 response to LPS (Kimura
et al., 2018). This reduction of inflammation is important
because activation of IL-6 and IL-1b can trigger cell death.
Indeed, we observed decreased cell death in infected
KEAP1/ cells, supporting a cytoprotective role of NRF2 in urothelial cells. Our finding that treatment with DMF reduced inflammatory cytokine production, the influx of immune cells into
the bladder mucosa while reducing infectious burden both
in vitro and in a mouse model, suggests that future work is warranted to determine the utility of DMF or similar agents to
dampen bladder inflammation in women with recurrent UTIs.
Further investigation of the impact of DMF and NRF2 activation
on long-term bacterial persistence in bladder and bladder immune response is also needed. Our work underscores the
importance of NRF2 activation for driving UPEC exocytosis
via RAB27B and balancing ‘‘good’’ and ‘‘bad’’ inflammatory responses to combat invasive pathogens without excessive tissue damage (Ambite et al., 2016a, 2016b).
In sum, our results demonstrate that activation of the NRF2
pathway is necessary for augmented innate host defense, i.e.,
RAB27B transcriptional upregulation and bacterial expulsion
along with other benefits such as lowered ROS and improved urothelial homeostasis. Our work suggests a model wherein
orchestration between recognition of UPEC, p62-mediated
KEAP1 engagement, and NRF2 activation ensures urothelial

(F) Western blot and densitometric quantitation of RAB27B protein in indicated cells. GAPDH, loading control. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01 compared with control by two-tailed unpaired Student’s t test.
(G) qRT PCR analysis of RAB27B gene expression in indicated cells. Data are presented as mean ± SD (n = 3 experiments). **p < 0.01 compared with control by
two-tailed unpaired Student’s t test.
(H) qRT PCR analysis of Rab27b in bladders from uninfected mice of the indicated genotypes. Data are presented as mean ± SD (n = 5 mice). ***p < 0.001
compared with WT by two-tailed unpaired Student’s t test.
(I) qRT PCR analysis of RAB27B expression in DCAP-treated cells. Data are presented as mean ± SD (n = 3 experiments). *p < 0.05 compared with vehicle control
by two-tailed unpaired Student’s t test.

10 Cell Reports 37, 109856, October 19, 2021

ll
Article

OPEN ACCESS

Figure 7. Dimethyl fumarate treatment activates NRF2 and reduces bacterial burden
(A) Immunofluorescence localization of NRF2 (green) in bladder epithelial cells treated with vehicle and DMF. Arrows indicate NRF2 expression. Scale bar, 20 mm.
Nuclei are stained blue.
(B) qRT-PCR analysis of NQO1, GCLC, and HMOX1 in DMF (50 mM)-treated urothelial cells. Data are presented as mean ± SD (n = 3 experiments). ***p < 0.001
compared with vehicle control by two-tailed unpaired Student’s t test.

(legend continued on next page)
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defense against invading UPEC. Given these important roles of
NRF2 in urothelial response to UPEC, future efforts should be
focused on identifying NRF2 or KEAP1 modulators such as
DMF and ROS regulators in the management of UTIs.
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Pierce Protein A/G Magnetic Beads

Thermo Fisher Science

Cat#88802

Critical commercial assays
ChIP-IT Express Chromatin Immunoprecipitation

Active Motif

Cat# 53008

TransIT Lenti

Mirus Bio

Cat# MIR 6603

Polybrene

Sigma-Aldrich

Cat# TR-1003

Milliplex ELISA kit

Millipore human cytokine

Cat# HCYTOMAG-60K
(Continued on next page)
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Continued
REAGENT or RESOURCE

SOURCE

IDENTIFIER

NE-PER Nuclear and Cytoplasmic
Extraction Reagents

Thermo Fisher Scientific

Cat#78833

5637

American Type Culture Collection and the
National Collection of Type Cultures (ATCC)

HTB9

293T

American Type Culture Collection and the
National Collection of Type Cultures (ATCC)

CRL-3216

Experimental models: Cell lines

Experimental models: Organisms/strains
C57B6

Jackson Laboratory

Nrf2/

Jackson Laboratory

B6.129X1-Nfe2l2tm1Ywk/J

KEAP1/ Validation primers: Human KEAP1 Forward:
ATCTTCGAGGAGCTCACCCT

This paper

N/A

KEAP1/ Validation primers: Human KEAP1 Reverse:
CACACTGTTGTGGTGGATGC

This paper

N/A

R1F1 Forward: CCCATGGACACACACTTCTT

This paper

N/A

R1F1 Reverse: GCCTGGCACAGTAAGTTCTAT

This paper

N/A

R2F2 Forward: GTCATTGGCATCTCGTTGTTTAC

This paper

N/A

R2F2 Reverse: CTATGTGCTATGCCGTGTTCT

This paper

N/A

Oligonucleotides

R3F3 Forward: GGGCTCTTTGAATGAGAGACAT

This paper

N/A

R3F3 Reverse: GGCTGGGTAAGGTTTGTGT

This paper

N/A

R4F4 Forward: GCCACTCGCAGTCCTGA

This paper

N/A

R4F4 Reverse: GGGAGAGCAGGTGTCAGATTT

This paper

N/A

UNTR Forward: CTGTACCTGGGGTTCATTCATT

This paper

N/A

UNTR Reverse: CAGTAAGCCGTTCACTCTCACA

This paper

N/A

KEAP1 sg1: CACCGCGGGCGGCTACTTCCGACAG

This paper

N/A

KEAP1 sg2: CACCGCGTGCCCCGTAACCGCATCG

This paper

N/A

Primers used for Q-PCR, see Table S1

This paper

N/A

Recombinant DNA
lentiCRISPR v2

Addgene

Cat# 52961; RRID: Addgene_52961

pSPAX2

Addgene

Cat#12260; RRID: Addgene_12260

pMD2.G

Addgene

Cat#12259; RRID: Addgene_12259

Prism v.9.0.1

GraphPad Software

https://www.graphpad.com/
scientific-software/prism/

Image Lab, version 6.1.0 build 7, standard edition

Life science research Bio-Rad

https://commerce.bio-rad.com/en-us/
product/image-lab-software

Fiji-ImageJ

ImageJ

https://imagej.net/software/fiji

Biorender licensed to Dr. Deepak Kumar/Mysorekar
Lab.

Biorender

https://app.biorender.com/

Software and algorithms

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Indira
Mysorekar (Indira.mysorekar@bcm.edu).
Materials availability
All unique/stable reagents generated in this study are available from the lead contact with a completed materials transfer agreement.
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Data and code availability
d
d
d

All data reported in this paper are available from the Lead Contact upon request.
This paper does not report original code.
Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon
request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial strain
A clinical cystitis isolate of Uropathogenic E. coli, UTI89, was grown statically for 17 h in Luria-Bertani (LB) broth at 37  C and used to
infect urothelial cells and mice.
Cell lines
Human urinary urothelial carcinoma cell line (5637, HTB9) (ATCC) was cultured in RPMI 1640 media with 10% fetal bovine serum in a
humidified atmosphere at 37 C with 5% CO2.
KEAP1/ 5637 bladder epithelial cell line was generated using CRISPR-Cas9.
Mice
All experimental procedures in mice were approved by the animal studies committee of the Washington University School of Medicine (Animal Welfare Assurance #A-3381-01). All mice experiments were performed according to approved protocols. In all experiments, adult female mice, 8–10 weeks of age were used. Mice were maintained under specified pathogen-free conditions in a barrier
facility and under a strict 12-h light/dark cycle. All mice were humanely euthanized at the end of each experiment. Nrf2 knock-out
mice were obtained from Jackson lab (Stock No: 017009) and backcrossed with wild-type C57BL/6J females for three to four generations. The resultant Nrf2 heterozygous females were then crossed with Nrf2 homozygous KO males to maintain the colony. All
progeny were routinely genotyped. Nrf2/ females were used in the study and C57BL/6J females were used as a wild-type control
for mice study. Adult female mice were anesthetized and inoculated transurethrally with 107 colony forming units (CFU) of UTI89 in
PBS as described previously (Hung et al., 2009). Transurethral infection experiments were repeated three times. n = 14 wild-type
mice and 14 Nrf2/ mice were used for quantifying urinary bacterial load. N = 10 animals of each genotype were used for quantifying
tissue bacterial load at indicated times post-infection.
METHOD DETAILS
Cell culture and UPEC infection in cultured cells
Bladder epithelial cells were infected as described previously (Wang et al., 2019). At 90% confluency (1.5 to 2 X105 cells), wild-type
5637 cells or DMF-treated 5637 cells were infected with UPEC at a multiplicity of infection (MOI) of 1:100, whereas KEAP1/ 5637 or
KEAP1 knockdown cells were challenged with UPEC at MOI of 1:300 so that the two genotypes would have a similar bacterial load at
0 hours post-infection (hpi). DMF-treated cells were washed with 1X DPBS three times to remove DMF and used as DMF pre-treated
cells or infected. After bacteria were added, plates were centrifuged at 120 g for 5 min and then incubated for 1 hour at 37  C. To
eliminate extracellular bacteria, cells were washed twice with 1X DPBS (GIBCO14190-136) and incubated in a medium containing
0.1 mg/mL gentamicin for an additional 23 hours (referred to as 24 hpi). Then, cells were washed and treated with 0.1% Triton
X-100 to release bacteria. Serial dilutions of bacteria were plated on LB agar and colony-forming units were counted. Each experiment was repeated three times with three technical replicates of each condition in each assay.
In vitro ROS measurement
Wild-type or KEAP1/ 5637 cells treated with vehicle or 10mM N-Acetyl-L-Cysteine were seeded in 96-well plates at 90% confluency. Cells were infected with UPEC or treated with 0.5 mg LPS or vehicle (PBS) as described above. At each time interval, one row of
uninfected and infected wells was thoroughly washed with 1X DPBS to remove dead bacteria and cells. The membrane-permeant
dye (20 , 7’-dichlorodihydrofluorescein diacetate (H2DCFDA, also known as dichlorofluores cin diacetate) was added at 10 mM and
incubated for 5 min at 37 C. Then, fluorescence was measured in an Envision plate reader (PerkinElmer, EnVision 2102 Multilabel
reader, Ex: 485nm /Em: 535 nm). At each time point, intensity in wells containing H2DCF alone was measured and subtracted
from all values. The experiment was repeated three times with three technical replicates of each condition per assay.
In vitro ROS imaging
5637 were seeded for 90% confluency and infected with the clinical UTI isolate UTI89. At indicated times, one row of uninfected and
infected wells was washed 3x with 1X DPBS. The membrane-permeant H2DCFDA solution was added at 10 mM concentration and
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incubated for 15 min at 37 C. Images were capture using epifluorescence microscopy (EVOS FL, Life Technologies). The experiment
was carried out three times with three technical replicate each time.
UPEC expulsion assay
The UPEC expulsion assay was performed as previously described (Miao et al., 2015). Briefly, 5637 cells were treated with vehicle,
100 mM tert-Butyl hydroperoxide, 10 mM N-Acetyl-L-Cysteine, control siRNA, NRF2 siRNA, or KEAP1 siRNA were infected with
UTI89 as described above. After one hour, cells were washed and incubated with 0.1 mg/mL gentamicin for one hour to kill extracellular bacteria. Initial bacteria load was determined by lysing cells with 0.1% Triton X-100. In parallel, other wells were washed
to remove gentamicin, and a 500 ml culture medium containing 100 mM methyl a-D-mannopyranoside and 25 mg/mL bacteriostatic
agent trimethoprim were added. After one and four hours (3 hpi and 6 hpi respectively), 50 ml of culture supernatant was removed and
plated onto LB plates to quantify the expelled bacteria. Plates were incubated at 37 C overnight, then colonies were counted. The
numbers of expelled bacteria were divided by the numbers of initial intracellular bacteria for each treatment group and expressed as a
percentage of bacterial expulsion. The experiment was repeated three times with three technical replicates of each condition per
assay.
In vitro DMF treatment
At 80%–90% confluency, 5637 cells were treated with 50 mM DMF or vehicle (DMSO) beginning one hour before or at the same time
as infection with UPEC. Cell lysates or isolated RNA were used to calculate the UPEC expulsion rate or for qRT-PCR analysis of NRF2
targets, respectively.
In vitro DCAP and rapamycin treatment
At 80%–90% confluency, 5637 cells were treated with 10 mM 2-((3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)amino)-2-(hydroxymethyl)propane-1,3-diol (DCAP) (Sigma, SML0515-5MG), 1 mM Rapamycin (LC Laboratories, R-5000) or Vehicle (DMSO) overnight (18 h). Cells were either fixed with 4% formaldehyde for immunofluorescence analysis or harvested for RNA for qRT-PCR analysis.
Immunofluorescence analysis of urothelial cells
5637 cells were seeded in 24 well glass-bottom plates (Cellvis, P24-1.5H-N) and infected as described above. After each time interval, one well was washed with DPBS and fixed in 4% paraformaldehyde for 20 min, or cells were treated with 10 mM LysoTracker for
15 min and then fixed. Cells were washed with DPBS and permeabilized with 0.1% Triton X-100 for 10 min, and then washed with
DPBS. Cells were blocked with 1% Bovine Serum Albumin (BSA) at room temperature (RT) for 1 hour and then incubated with antiNRF2 or anti-p62 or anti-Keap1 antibody (1:200) or LysoTracker at 4 C overnight. Then, cells were washed three times with DPBS
and incubated with respective Alexa Fluor antibodies for 1 hour at RT. Cells were then washed three times with DPBS and mounted in
ProLong Gold Antifade Mountant with DAPI (Thermo Fischer Scientific, Eugene, OR). Slides were imaged on a Zeiss LSM880 laser
scanning confocal microscope (Carl Zeiss Inc, Thornwood, NY).
Nuclear fraction isolation and quantification
In a 6 well plate, 90% confluent 5637 cells were infected as described before. At each time point, infected and uninfected wells were
washed three times using 1X DPBS, and cells were harvested using Trypsin-EDTA. Control and KEAP1/ cells were harvested for
nuclear fractionation. Nuclear fraction was extracted from the cell suspension using a nuclear protein extraction kit. 10 mg of protein
was loaded onto 4%–15% gel (Mini Protean TGX, stain-free gel) and transferred to the PVDF membrane. Membranes were blocked
either with 1.5% BSA, then incubated with anti-NRF2 antibody or anti-TBP (Tata Binding Protein) overnight at 4 C. The next day,
membranes were washed three times with 0.1% tween 20-PBS. And incubated with appropriate secondary antibodies for 1 hour
at RT, washed three times with 0.1% tween 20-PBS, and developed using ChemiDocTM MP imaging system with ImmobilonHRP substrate (Millipore-Sigma, WBKLS0500). TBP was used as a loading control for nuclear proteins. Bio-Rad Image Lab software
(6.0.1) was used to perform densitometry analysis. Experiments were repeated at least three times.
Western blotting analysis
Protein from uninfected and infected wild-type or KEAP1/ 5637 cells were harvested in RIPA lysis buffer after each time point postinfection. Protein was quantified with a BCA assay, and 10 mg of protein was loaded onto a 4%–15% gel (Mini Protean TGX, stain-free
gel), electrophoresed, and transferred to PVDF membrane. Membranes were blocked with 5% milk powder for 1 hour at RT, then
incubated with primary antibodies overnight at 4 C. Then, membranes were washed three times with 0.1% tween 20-PBS, incubated
with suitable secondary antibodies for 1 hour at RT, washed three times with 0.1% tween 20-PBS, and developed with the ChemiDocTM MP imaging system with Immobilon-HRP substrate. GAPDH was used as a loading control. Bio-Rad Image Lab software
(6.0.1) was used to perform densitometry analysis. Experiments were repeated three times.
Immunoprecipitation analysis
Immunoprecipitation (IP) was carried out as per Cold Spring Harbor Protocols. Briefly, uninfected and UPEC-infected cells were
lysed at different times post-infection in IP lysis buffer. Protein lysate was measured and precleared with normal rabbit IgG and Pierce
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Protein A/G Magnetic Beads for 2 hours. Antibody and beads were separated with a magnet, and the supernatant was incubated with
rabbit polyclonal anti-NRF2 antibody overnight at 4 C. Then, 50% slurry of Protein A/G magnetic beads were added and incubated
for 2 hours at 4 C. The antibody-bead conjugate was separated with a magnet, washed three times with wash buffer, and boiled in
Laemmli buffer for 10 min. Western blotting with anti-KEAP1 antibody was performed according to standard protocols. Secondary
antibodies from Rockland Immunochemicals were used for detection. Experiments were repeated three times.
Quantitative RT-PCR analysis
RNA from uninfected and infected wild-type or KEAP1/ 5637 cells was extracted with Trizol and treated with DNase. Then, Superscript II was used to synthesize cDNA from 1 mg of RNA. Syber green PCR master mix was used for quantitative PCR (Bio-Rad,
CFX96TM Real-Time System, C1000 Touch thermal cycler) with specific primers (Table S1). GAPDH was used as a housekeeping
gene. For each primer set, efficiency and melt curve were estimated. The primer sets included in this study have more than 90%
efficiency. The experiment was repeated three times with three technical replicates of each condition per assay. Values from vehicle
treatment were used to calculate the relative fold expression in treated or infection conditions.
siRNA treatment
siRNAs against KEAP1 (assay ID, s18981) and NRF2 (assay ID, s9492), and negative control siRNA were purchased from Thermo
Fisher Scientific. 5637 cells were seeded at 50% confluency and transfected with siRNA according to the Lipofectamine2000 protocol (Invitrogen, 52887). All siRNAs used in this study were tested for knockdown efficiency by quantitative RT-PCR. After 48 hours,
cells were subjected to in vitro infection assay, in vitro expulsion assay, or in vitro ROS measurement.
ELISA analysis
Cultured supernatants from uninfected and infected wild-type or KEAP1/ 5637 cells or sera from mice in indicated treatment group
or genotype were collected, and a Multiplex ELISA kit was used to measure IL-6 and IL-1b levels per the manufacturer’s protocol.
Promoter analysis
The online tool ConTra v3 was used to visualize and explore predicted transcription factor binding sites in the core RAB27B promoter,
defined as the 500 base pairs upstream of the transcription start site. Homo sapiens (hg-19) was used as a reference organism, and
the V$NRF2_Q4 matrix and TRANSFAC20113 database were used for prediction.
Chromatin immunoprecipitation (ChIP) analysis
ChIP was performed with a ChIP-IT kit (Active motif, #53008) as per the manufacturer’s protocol. Briefly, 5637 cells were cultured in
15 cm plates, and at 90% confluency, cells were fixed in 1% formaldehyde in a minimal RPMI culture medium. The crosslinking was
terminated with a Glycine-PBS stop solution. Cells were then washed with PBS, collected, and dounced in lysis solution in an ice-cold
Dounce homogenizer. Nuclei were pelleted by centrifugation and sheared at 4 C in a Covaris E220 Focused-ultrasonicator with the
following settings: peak power 165, duty factor 10.0, 200 cycles per burst, total 400 s. The sheared chromatin was then incubated
overnight at 4 C with an anti-Nrf2 antibody or control normal Rabbit IgG in the presence of magnetic protein G beads. Then, beads
were separated and washed with ChIP buffers 1 and 2. Beads were treated with elution buffer AM2 and reverse crosslinking buffer,
and the resulting supernatant was separated from magnetic beads. The supernatant was heated at 95 C for 15 mins and treated with
proteinase K for 1 hour. Proteinase K stop solution was then added. Similarly, sheared chromatin was processed for obtaining ‘input’
DNA. Sheared DNA was mixed with 2 ml of 5 M NaCl and 88 ml ChIP buffer 2, heated to 95 C, and treated with proteinase K for 1 hour.
Proteinase K stop solution was then added. The DNA was immediately used for PCR with primer sets covering the indicated promoter
regions. Controls included a primer set for a non-transcribed region and a no-template control. PCR products were separated on a
1.8% agarose gel and imaged with a ChemiDocTM MP imaging system. The experiment was repeated three times.
CRISPR-Cas design
sgRNA design and guide oligo synthesis
A specific region from the KEAP1 genomic sequence (NC_000019.10:c10503378-10486120 Homo sapiens chromosome 19,
GRCh38.p7) was selected to design a guide RNA (sgRNA) on the Broad Institute Web portal. Two guide sequences, sg1 and sg2,
covering the desired region of KEAP1 were selected from 10 candidate guide sequences that contained the S. pyogenes Cas9
(spCas9) PAM sequence (NGG). The reverse complement of each guide sequence was determined, and a BsmBI restriction site
was added flanking the sequences. Oligos with restriction sites were obtained from Integrated DNA Technologies (Coralville IA, USA).
Cloning and production of CRISPR lentivirus
The vector lenti-CRISPR v2 (Sanjana et al., 2014) (a gift from Feng Zhang, Addgene plasmid #52961, RRID: Addgene_52961) was
linearized with BsmBI (NEB, R0580S), dephosphorylated, and gel purified by standard methods. Guide oligos and the reverse complementary sequences were annealed and phosphorylated, ligated to the purified linear plasmid overnight at 16 C, then transformed
into chemically competent bacteria. The isolated plasmid was sequenced to confirm the guide oligo sequence. For lentivirus production, Human Embryonic Kidney (HEK) 293T cells were (grown in DMEM medium supplemented with 10% FBS) were co-transfected
with cloned lentiCRISPR v2 and packaging plasmids pSPAX2 (Addgene plasmids #12260 and #12259, RRID: Addgene_12260 and
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Addgene_12259, respectively, both gifts from Didier Trono) by using TransIT Lenti (Mirus Bio, MIR 6603). After 48 hours, the supernatant was collected to harvest the virus.
Transduction and screening for the knockout
5637 cells were transduced with CRISPR lentivirus (derived from sg1 and sg2) with polybrene. After 24 hours, transfected cells were
selected by incubating for seven days in 2-5 mg/ml Puromycin. Cells were then screened for deletion of specific regions by PCR with
KEAP1 primers.
Treatment of mice with dimethyl fumarate (DMF)
Mice were treated with DMF as described (Kornberg et al., 2018). Briefly, DMF was suspended in 0.8% methylcellulose (Sigma-Aldrich, catalog # 64632) and warmed to 37 C with constant stirring. Mice were then orally gavaged with 100 mg/kg DMF or vehicle
control (0.8% methylcellulose solution) 24 hours before transurethral infection and then at 24- and 48 hours post-infection (hpi). Urine
was collected at 24, 48, and 72 hpi, and mice were sacrificed at 48 and 72 hpi. N = 12 mice were used in each group at 24 and 48 hpi
time points, 10 animals in each group at 72 hpi.
QUANTIFICATION AND STATISTICAL ANALYSIS
Urine analysis and inflammation score
Mouse urine sediments were obtained and fixed for 15 minutes in acetic acid/alcohol and Papanicolaou stained according to the
manufacturer’s instructions (Thermo Fisher). Stained urine sediments were scored in a blinded manner by light microscopy on a scale
from 0 to 4, where 0 indicates < 1 and 4 indicates > 20 polymorphonuclear leukocytes/high-powered field, as previously described
(Stemler et al., 2013). For imaging of exfoliated cells in the urine, urine sediments were treated with 10 mM NAC or with the vehicle for
5 min. Cells were then incubated with 10 mM H2DCF and DAPI and smeared onto glass slides. Smears were analyzed by epifluorescent microscopy (EVOS FL, Life Technologies). Urinary bacterial load was quantified as described previously (Wang et al., 2012a).
Briefly, urine samples obtained from infected mice at indicated time points were serially diluted in phosphate-buffered saline (PBS),
and 5 mL of each dilution was spotted onto LB plates six times. Bacterial titers were calculated as log10 CFU/ml.
Bladder tissue CFU analysis
Bladders were harvested aseptically, and bladder tissue was homogenized in 1 mL of sterile 1X DPBS using QIAGEN TissueLyser II.
The lysate was briefly centrifuged at 300 rpm for 5 minutes and the supernatant was collected. Serial dilutions of supernatant were
plated on LB agar and colony-forming units were counted. Bacterial titers were calculated as log10 CFU/ml.
Cell count using a hemocytometer
Control and KEAP1/ cells were trypsinized at 24 hpi. Cells were diluted with Trypan Blue and viable cells were counted using a
hemocytometer. Viable cell count was expressed as a number of cells per ml for each genotype. The experiment was repeated three
times with three technical replicates of each condition per assay.
Image analysis
Fiji image analysis software with the co-localization plugin was used to calculate the extent of co-localization between KEAP1 and
LysoTracker (a total of nine cells from 3 representative images of 0h and 6 hpi were taken) and between p62 and LysoTracker (a total
of five cells from 3 representative images of 0h and 6 hpi were taken). Coloc2 analysis with Costes method was used. Pearson’s
R-value was used to determine the extent of co-localization. The R-value near 1 was considered significant co-localization. Values
were plotted from Coloc 2 analysis of data at 0 and 6 hpi. An unpaired t test was used to calculate statistical significance.
Statistical analysis
Quantitative data were presented as mean ± standard deviation (SD) of the number (n) of replicates or animals (indicated in each
figure). Statistical analyses were performed using GraphPad Prism version 9.0.1 (GraphPad Software, La Jolla, CA, USA). Unpaired
Student’s t tests were used to determine statistical significance in experiments examining two parameters. Two-way ANOVA
was used for experiments with multiple time points. One-way ANOVA was used for experiments with multiple independent groups.
Non-parametric Mann-Whitney test was used in inflammation score analysis. p < 0.05 was considered statistically significant. P
values are as follows: ns non-significant, * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.001.
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Supplementary Table S1. List of primers used for q-RT-PCR

Name
Human NQO1 Forward
Human NQO1 Reverse
Human GCLC Forward
Human GCLC Reverse
Human HMOX1 Forward
Human HMOX1 Reverse
Human RAB27B Forward
Human RAB27B Reverse
Human IL-6 Forward
Human IL-6 Reverse
Human IL-1b Forward
Human IL-1b Reverse
Human GAPDH Forward
Human GAPDH Reverse
Mouse 18s Forward
Mouse 18s Reverse
Mouse Nrf2 Forward
Mouse Nrf2 Reverse
Mouse Nqo1 Forward
Mouse Nqo1 Reverse
Mouse Gclc Forward
Mouse Gclc Reverse
Mouse Hmox1 Forward
Mouse Hmox1 Reverse
Mouse Rab27b Forward
Mouse Rab27b Reverse

Sequence
GGCTGGTTTGAGCGAGTGTT
CCAAAAGGAGCAAGAGAAAGCC
CCCCTCCTCCAAACTCAGAC
GCAGTACCACAAACACCACA
CTTTTCAGAAGGGCCAGGTGA
GTAGACAGGGGCGAAGACTG
TAGACTTTCGGGAAAAACGTGTG
AGAAGCTCTGTTGACTGGTGA
ACTCACCTCTTCAGAACGAATTG
CCATCTTTGGAAGGTTCAGGTTG
ATGATGGCTTATTACAGTGGCAA
GTCGGAGATTCGTAGCTGGA
GAAGGTGAAGGTCGGAGT
GAAGATGGTGATGGGATTTC
CGGCTACCACATCCAAGGAA
GCTGGAATTACCGCGGCT
AACAGAACGGCCCTAAAGCA
GGGGTTCACGCATAGGAGCA
AGGATGGGAGGTACTCGAATC
AGGCGTCCTTCCTTATATGCTTA
GGGGTGACGAGGTGGAGTA
GTTGGGGTTTGTCCTCTCCC
AAGCCGAGAATGCTGAGTTCA
GCCGTGTAGATATGGTACAAGGA
TCGGGAAAAACGTGTGGTTTA
TTCAAGAAGCTCTGTTGACTGG

